|Home Page||Biographical Sketch||Awards & Distinctions||Intellectual Property||Advisory
|Invited Presentations||National & International Activities||Publications List & Index||Books|
|MRLS||ELISA Testing -- A Regulatory Revolution||World Racing Rules on Equine Medications|
Thomas Tobin (TT), Veterinarian, Dublin, 1964, Pharmacologist MSc, Guelph, 1966, PhD Toronto, 1970, Instructor>Associate Professor, Michigan State University, 1970-1975, Equine Pharmacology, Therapeutics and Toxicology (EPTT) program at the University of Kentucky, 1975-todate. In 1979 organized the Third Int. Symp. on Equine Medication Control, in 1980 became a Diplomate of the America Board of Toxicology, DABT. http://www.ca.uky.edu/gluck/index.htm. in 1981 authored and published Drugs and the Performance Horse, a 450 page text. In 1983 testified before Congress on the “Corrupt Horse Racing Practices”act; activity on this bill thereafter ceased.
1985 TT began the research that introduced ELISA testing to horse
racing. Commercialization of
this technology led to the creation of WTT ELISA TESTS, later sold to
Neogen Corp (www.neogen.com)
Neogen Lexington now employs 100, brings in $50M/year and the ELISA IP
yields a significant
In 1988 TT became Director of
the UK Graduate Center for Toxicology, brought in an $800K NIEHS
Training Grant and developed minority programs.
By 1993 core faculty and student admissions were up three-fold,
extramural funding had increased from 0 to $800K per year and new
courses on “Ethics in scientific
research” and “Risk assessment”
had been developed. When NRC
In 1994, TT organized and
published an international workshop, “Testing for Therapeutic
Medications, Environmental and Dietary Substances in Racing Horses,”
that brought 70 international industry leaders to
In 1996, TT
and David Granstrom investigated new therapeutic approaches to Equine
Protozoal Myelitis (EPM), rapidly establishing the therapeutic efficacy
of diclazuril and toltrazuril. A
patent in this area was granted (US patent #5,883,095, 1999) and
licensed to Bayer Animal Health; in July 2001, Bayer Marquis® (Bayer
DVM.com – Marquis® ) became the first FDA-approved treatment for EPM.
More recently, diclazuril as Protazil® has been brought to market unde
this same patent by Merck Animal Health.
In 1998 the industry focused on Clenbuterol. A series of LC-MS-MS based studies led to the publication of a highly sensitive serum test for Clenbuterol, allowing much more sensitive and reliable regulatory control of therapeutic medications than previously. In 1998 TT also organized and published a Testing Integrity Program [TIP] seminar on furosemide.
In 2000, at the direction
of the Kentucky Racing Commission (KRC), TT developed a series of
nationally accredited continuing education short courses for
practitioners and regulatory veterinarians in
In May 2001, TT chaired the Toxicology Working Group investigating the 2001 Mare Reproductive Loss Syndrome (MRLS) and his group temporarily redirected to work on MRLS. Within three weeks the Eastern Tent Caterpillar was identified as a central factor in MRLS. Work in 2002 clearly linked MRLS to the Eastern Tent Caterpillar; in July 2002 TT proposed that MRLS followed an unusual probabilistic setal emboli model, in 2003, MRLS was shown to follow a unique probabilistic mathematical model, Accelerated Failure Time Analysis, and the biologically unique pathogenesis for MRLS based on septic penetrating setal fragments (www.jarvm.com/articles/Vol2Iss2/TOBINJARVMVol2No2.pdf) was formally communicated and the copyright registered. In August 2002, TT and David Powell organized the first workshop on the Mare Reproductive Loss Syndrome, published in May 2003.
In 2003 the program
contributed to the writing of the National HBPA Proposed Policy on Drug
Testing and Therapeutic Medication (http://hbpa.org/resources/MedicationPolicy.pdf)
and focused on developing fully validated quantitative analytical
methods for agents abused in racing horses.
In 2003 it was decided that it would be in the best interests of
the racing industry in
In 2005 the program began synthesizing series of certified reference standards and stable isotope internal standards for therapeutic medications, based on earlier thresholds research pioneered by the program, and currently in the process of being licensed. In July 2006 US Patent # 7,074,843 for a novel veterinary sedative and tranquilizer was awarded and a unique pathogenesis for oligofructan associated laminitis was proposed.
More recently work on the
certified reference standards and stable isotope internal standards for
use in quantitative forensic work in equine medication control
continues. The program has
generated research support from the Kentucky Science and Engineering
Foundation [KSEF] the Racing Medication and Testing Consortium [RMTC]
and National and local Horsemen’s Benevolent and Protective
Association organizations [HBPAs] the Kentucky Equine Drug Research
Council and other equine groups in support of the creation and
commercial availability of appropriate reference standards for use in
racing chemistry. The
research/intellectual property goal is to create and provide certified
reference standards and stable isotope internal standards for the 50 or
so therapeutic medications used in horses in training, and whose use is
regulated by quantitative forensic chemistry. This work is being carried
out in association with Frontier Biopharm Inc. of
Medications for which
certified reference standards and stable isotope, usually deuterated,
internal standards have been developed and are have been or are being
brought to market include phenylbutazone, flunixin, ketoprofen,
methocarbamol, guafenesin, clenbuterol, procaine and furosemide.
Additionally, a number of certified reference standards for drug
metabolite fragments/regulatory analytes include unlabeled and
deuterated 3-hydroxylidocaine, 3-hydroxymepivacaine, hydroxyethyl
promazine sulfoxide, carboxydetomidine and Hydroxydetomidine, with
approximately 5 corticosteroid therapeutic medications scheduled for
stable isotope reference standard development.
In 2008 the third edition
of the National Horsemen's Benevolent and Protective Association Policy
on Drug Testing and Therapeutic Medication Regulation was assembled by
the program in cooperation with Mr. Kent Stirling, Chairman of the
National HBPA Medication Committee and Executive Director of the Florida
Horsemen's Benevolent and Protective Association.
In 2009 Mr. Kent Stirling and TT were jointly awarded the 2008
National Horsemen's Benevolent and Protective Association Industry
Service Award. In March 2011
the first of a sequence of metabolites/regulatory
analytes/deuterated standards certified reference standards were
licensed to Frontier BioPharm. In February 2012 the fourth
edition of the HBPA mediction book,
now entitled “World Rules for Equine Drug Testing and
Therapeutic Medication Regulation” was published and the first
certified reference standard for myo-Inositol TrisPyroPhosphate was
released through the FrontierBiopharm LLC licensing agreement.